Articles tagged with Glioblastomas
Glioblastoma multiforme (GBM) is a highly aggressive brain tumor resistant to current therapies. Researchers at the University of California, San Francisco, have identified PDGFR-alpha and SULF2 as potential therapeutic targets for GBM treatment. Knocking down SULF2 expression decreased cell growth in human GBM cell lines.
A team of researchers has identified a potential new therapeutic target for the treatment of glioblastoma multiforme (GBM), a highly aggressive form of brain cancer. They found that protein SULF2 is expressed in primary human GBM tumors and cell lines, and its expression is associated with abnormal activation of signaling pathways down...
Researchers identified genetic alterations affecting proteins known as histones in 48 pediatric glioblastomas, with 36% of cases featuring histone mutations. These mutations, which occur rarely in adult glioblastoma, may hold key to developing new treatments for the most malignant type of brain tumor.
Researchers have identified a new pathway that targets the root cause of glioblastoma resistance, paving the way for more effective treatments. By understanding how this complex signaling process works, scientists hope to develop novel therapies to improve patient outcomes and extend survival rates.
A University of Illinois study found that personalized prognostic tools and gene-based therapies can improve the survival and quality of life of glioblastoma patients. The researchers discovered new general and clinical-dependent gene profiles that can be used to predict patient outcomes and select targeted therapies.
A new study uses weather forecasting models to predict the spread of brain tumors, demonstrating the feasibility of a mathematical approach. The model, known as LETKF, provides accurate and efficient predictions of tumor growth and spread, taking into account errors in model parameters and measurement uncertainties.
A team of researchers identified APNG as a contributor to GBM resistance to temozolomide, with high nuclear expression correlating to poorer survival. Monitoring APNG levels may provide insight into patient response to temozolomide treatment.
Researchers identified a key protein mutation that enables brain tumors to invade healthy brain tissue. Excessive epidermal growth factor receptor (EGFR) signals trigger the production of GBP1, rendering tumors more invasive and allowing them to spread into surrounding tissue.
Four US clinical centers have begun providing access to Novocure's Tumor Treating Fields (TTFields) device for treating recurrent GBM, a deadly brain tumor. The device has shown clinical efficacy comparable to active chemotherapies with better quality of life.
A Massachusetts General Hospital study found that about 5% of glioblastomas contain extra copies of two or three key genes, which may explain the limited success of targeted therapies. The research team identified mosaic subpopulations of cells within tumors, each with its own unique genetic mutations and functions.
Scientists identified a novel gene mutation causing glioblastoma, a common type of malignant brain tumor. Two existing drugs targeting this mutation effectively prolonged the survival of mice, offering new hope for patients.
Researchers are investigating a novel gene therapy approach using LG631 to improve tolerance and effectiveness of chemotherapy for glioblastoma, a devastating brain cancer. The study aims to prevent damage to bone marrow, enabling patients to receive higher doses with fewer side effects.
A study by Bo Hu and Shi-Yuan Cheng found that PDGFR-alpha overexpression in glioblastomas triggers a signaling cascade promoting tumor growth and invasion. Manipulating Dock180 to block this pathway inhibits PDGFR-alpha's role in glioma tumorigenesis.
Researchers discovered a molecular pathway driven by PDGFR-alpha that promotes the aggressive nature of a significant proportion of glioblastomas. Overexpressed in GBMs, this pathway triggers signaling cascades leading to tumor growth and invasion. Manipulating Dock180 phosphorylation disrupts this pathway, resulting in failed tumor pr...
Researchers at VCU Massey Cancer Center have discovered a mechanism by which glioblastoma multiforme promotes neurodegeneration, leading to neuron death. AEG-1, an oncogene overexpressed in brain tumors, inhibits expression of EEAT2, a glutamate transporter, resulting in excitoxicity and excessive glutamate levels.
A study published in Cancer Cell reveals that the coupling of proteins FoxM1 and beta-catenin promotes glioblastoma development. The researchers found that this protein connection supports the self-renewal and differentiation of glioma-initiating cells, cancer stem cells thought to drive glioblastoma multiforme.
Scientists at Sanford-Burnham and Salk Institute developed a method to combine peptides and nanoparticles to eliminate glioblastoma in previously untreatable mouse models. The nanosystem proved effective in treating two different mouse models, curing most tumors and significantly delaying tumor development.
Researchers discovered that glioblastoma cells depend on large amounts of cholesterol for growth and survival, and that pharmacologically depriving them of cholesterol leads to death. This new strategy may lead to significantly more effective treatments for patients with this lethal form of brain cancer.
Researchers found that glioblastoma cells need large amounts of cholesterol to grow and survive. Cholesterol-manipulating drugs could potentially lead to significant tumor cell death if this laboratory work is confirmed in larger studies.
A novel gene therapy approach combining with radiation therapy has been found to be safe and effective in treating glioblastoma multiforme, a deadly form of brain cancer. The treatment stimulates an immune response against the tumor, producing an 'immunogene therapy' effect.
Researchers at Ohio State University discovered that indirubin blocks the migration of glioblastoma cells and endothelial cells, preventing tumor growth and spread. This compound, derived from Indigo plants, may offer a novel therapeutic strategy for treating deadly brain tumors.
Researchers have discovered potential regulatory networks in glioblastoma using microRNAs and transcription factors. The study identified 54 feed-forward loops with functions important to carcinogenesis and unique functions specific to each FFL.
A Phase I clinical trial found that the experimental vaccine ICT-107 targets six antigens found on glioblastoma cells and three on cancer stem cells, improving immune responses and progression-free survival rates in patients. The study also showed that targeting these antigens may be a viable strategy for treating glioblastoma.
A new glioblastoma vaccine has demonstrated safety and effectiveness in a Phase 2 clinical trial, extending median survival to 11 months for patients with recurrent brain cancer. The vaccine was found to induce an immune response against tumor-specific targets, suggesting potential for improved treatment outcomes.
Survival rates for wealthier patients with glioblastoma have improved since 2000, while those in poorer areas and older than 70 have remained stagnant. The addition of temozolomide to post-operative radiation therapy has been shown to improve overall survival in younger patients.
The RTOG 0525 Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma found no significant improvement in overall patient survival or disease progression for patients who received dose-intensive temozolomide plus radiotherapy. However, the trial demonst...
Researchers at IDIBELL found that Nutlin-3a stimulates the p53 pathway, inducing apoptosis and cellular senescence in brain cancer cells. This study suggests MDM2 antagonists may be new therapeutic options for glioblastoma treatment.
A team of University of Cincinnati researchers is sequencing individual glioblastoma genomes and tracking abnormalities in the bloodstream to establish personalized biomarkers. The study aims to guide treatment efforts and identify new therapeutic targets for this aggressive brain tumor.
A personalized dendritic cell vaccine has been shown to increase median survival time in patients with glioblastoma, a deadly form of brain cancer. The vaccine was found to be effective in patients with the mesenchymal subtype of glioblastoma, which accounts for about one-third of all cases.
Glioblastoma cells can transform into blood vessel cells when oxygen is scarce, making treatment efforts less effective. This transformation allows the tumor cells to continue receiving nutrients and oxygen, leading to a resurgence of cancer growth.
A recent study published in the New England Journal of Medicine found that losing the NFKBIA gene promotes glioblastoma multiforme growth and reduces survival. Restoring this gene may improve survival for certain patients with glioblastoma, as it inhibits tumor cell growth and increases sensitivity to chemotherapy.
Researchers at Stanford Medicine have discovered a gene deletion in up to one-fourth of glioblastoma cases, a type of brain cancer with poor survival prospects. The deletion contributes to tumor growth, resistance to therapy, and worsens patient outcomes.
Phase III trial data suggests Tumor Treating Fields (TTF) therapy increases median survival time and improves quality of life scores compared to standard chemotherapy. Younger patients and those with better functional status show an impressive survival advantage.
A new vaccine has been shown to extend survival for patients with glioblastoma, the most deadly form of brain cancer, by eliminating aggressive cancer cells carrying the EGFRvIII marker. The study found that adding the vaccine to standard therapy improved median survival time from 15 months to 26 months.
A team of researchers has discovered genetic changes in glioblastoma, a common type of primary brain cancer, that contribute to its aggressiveness. The study found that tumors with rearrangements in receptor genes are more common than previously thought, suggesting new targets for therapies.
A novel combination therapy of temozolomide and a Notch inhibitor has been shown to be highly effective in reducing tumor growth and recurrence in glioblastoma multiforme. This approach aims to target cancer stem cells, which are resistant to traditional therapies.
Researchers have identified a new cellular communication mechanism in glioblastoma cells, which could be targeted to slow tumor growth. If blocked, this pathway may significantly reduce GBM malignancy.
Researchers at Wake Forest University Baptist Medical Center have identified a way to target and destroy Glioblastoma multiforme (GBM) cells without harming healthy cells. The breakthrough allows for new possibilities in cancer research, potentially leading to less toxic and invasive treatments.
The study enrolled 237 patients with recurrent GBM and found that NovoTTF was as effective as the best available chemotherapies without the toxicity. Patients treated with NovoTTF lived longer and experienced fewer infections compared to chemotherapy.
A new drug, PD-0332991, has been found to effectively block the growth of glioblastoma cells in laboratory tests and animal studies. The agent targets specific molecules that drive cell division in cancer cells, offering a potential new treatment option for this deadly form of brain cancer.
Researchers at Stanford University School of Medicine have found that disrupting the SDF-1/CXCR4 interaction can prevent the recruitment of vasculogenic cells to the tumor site, blocking postirradiation development of functional tumor vasculature and tumor regrowth. This approach may be applicable to treating glioblastoma multiforme.
Researchers at Stanford University School of Medicine found that blocking blood vessel formation prevents brain tumor recurrence in mice. Disrupting the SDF-1/CXCR4 interaction prevented tumor regrowth by abrogating functional tumor vasculature.
The Cancer Genome Atlas reveals four molecular subtypes of glioblastoma multiforme (GBM), the most common form of malignant brain cancer in adults. Researchers found that response to chemotherapy and radiation differed by subtype, with some subtypes experiencing a 50% slower disease progression.
Researchers at UNC Lineberger Comprehensive Cancer Center identified four distinct molecular subtypes of GBM, each associated with a specific disease process. The study provides a solid framework for investigation of future targeted therapies that may improve the prognosis of this devastating cancer.
Researchers from M.D. Anderson Cancer Center discovered that cancer stem cells inhibit T cell response and evade immune attack on glioblastoma multiforme. Differentiation of these cells into other neural types can restore the immune response, offering new hope for treatment.
Researchers have identified two genes, C/EPB and Stat3, which are responsible for the most aggressive forms of human brain cancer. These genes work together to transform normal brain cells into highly aggressive cells, making them a major target for new treatments.
Researchers at the University of Central Florida have found a protein, TRPC6, that could hold the key to treating GBM, a type of malignant brain tumor. Knocking down this protein's expression can stop tumor growth and spread.
Researchers at University Hospitals Case Medical Center report promising results from a study treating glioblastoma multiforme with Gamma Knife radiosurgery, increasing patient survival rates by almost four months compared to traditional radiotherapy alone.
A Phase II study shows Avastin significantly increases response rates, progression-free survival times and survival rates in patients with recurrent glioblastoma. The treatment was found to be effective both alone and in combination with chemotherapy, improving patient outcomes and quality of life.
Researchers funded by NIH have found a key factor in the spread of aggressive brain cancer glioblastoma multiforme (GBM). A small designer protein can block the activity of a protein fragment that stimulates GBM cell migration, suggesting a potential new therapy target.
Researchers found that STAT3 inhibits the growth and self-renewal of glioblastoma stem cells, suggesting a promising target for cancer therapy. The study demonstrates the potential of STAT3 inhibitors to stop tumor formation and offers a new approach to treating this devastating brain cancer.
Glioblastoma, the deadliest form of brain cancer, has shown promise in treating with an engineered antibody that shuts down tumor growth. Researchers at Lombardi Comprehensive Cancer Center successfully tested the antibody in human cells and animal studies.
A network of 31 mutated genes has been identified as the driving force behind glioblastoma growth. Annexin A7, a vital guard gene, is lost in most cases, allowing tumors to flourish. The discovery offers new therapeutic targets and potentially extends patient survival.
Recent JAMA studies on brain cancer and altered genes have made significant progress in understanding the root causes of this deadly disease. Researchers identified seven genes linked to survival among glioblastoma multiforme patients, paving the way for potential new therapies.
Researchers at UNC School of Medicine have identified a compound that could treat secondary glioblastoma multiforme (GBM), a type of brain tumor. By replenishing α-ketoglutarate, they reversed the effects of IDH1 gene mutation, which contributes to tumor growth.
Researchers at Duke University have identified a receptor on human glioblastoma cells that may be an appropriate target for therapies. Activation of the neurokinin 1 receptor leads to increased cell growth, but blocking this activity can reduce cell death and potentially stall cancer growth.
Researchers at UT Southwestern Medical Center have identified a new biological indicator, RIP1, that may help identify the most aggressive forms of adult brain cancer. High levels of RIP1 are commonly found in glioblastoma tumors and are associated with poor prognosis and resistance to chemotherapy.
The study found that treatment with cediranib reduced edema and improved survival in mice with glioblastoma tumors. Mice receiving the drug lived significantly longer than controls, despite continued tumor growth.
The EORTC-NCIC trial found that adding chemotherapy to radiotherapy significantly increases survival in glioblastoma patients, with improved outcomes seen across all clinical prognostic subgroups. The study suggests testing tumour MGMT gene methylation status to identify patients most likely to benefit from this treatment.
Researchers at Bonn University discovered a critical improvement in treating glioblastoma, the most aggressive and common brain tumor. The combination of two drugs increased average survival time to 23 months, with some patients surviving over four years. Further investigations are needed to optimize this therapy.